SAN DIEGO, Dec. 15, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) announced today the planned, oral presentation of clinical efficacy and safety data for both of its lead products in sexual medicine -- Vitaros® for erectile dysfunction ("ED") and Femprox® for Female Sexual Arousal Disorder ("FSAD") -- at the Biennial Meeting of the African Society for Sexual Medicine ("ASSM"), taking place in Dakar, Senegal, from December 15 to December 17, 2011.
